vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and Mega Matrix Inc (MPU). Click either name above to swap in a different company.
Mega Matrix Inc is the larger business by last-quarter revenue ($6.1M vs $3.9M, roughly 1.5× Citius Pharmaceuticals, Inc.). Mega Matrix Inc runs the higher net margin — -177.4% vs -238.2%, a 60.7% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
CTXR vs MPU — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $6.1M |
| Net Profit | $-9.4M | $-10.8M |
| Gross Margin | 80.0% | 47.7% |
| Operating Margin | -228.7% | -156.3% |
| Net Margin | -238.2% | -177.4% |
| Revenue YoY | — | -40.9% |
| Net Profit YoY | 8.6% | -291.1% |
| EPS (diluted) | $-0.38 | $-0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | — | ||
| Q3 25 | — | $6.1M | ||
| Q2 25 | — | $7.1M | ||
| Q1 25 | — | $7.7M | ||
| Q3 24 | — | $10.3M |
| Q4 25 | $-9.4M | — | ||
| Q3 25 | — | $-10.8M | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-2.5M | ||
| Q3 24 | — | $-2.8M |
| Q4 25 | 80.0% | — | ||
| Q3 25 | — | 47.7% | ||
| Q2 25 | — | 58.5% | ||
| Q1 25 | — | 55.8% | ||
| Q3 24 | — | 58.5% |
| Q4 25 | -228.7% | — | ||
| Q3 25 | — | -156.3% | ||
| Q2 25 | — | -21.6% | ||
| Q1 25 | — | -32.8% | ||
| Q3 24 | — | -26.0% |
| Q4 25 | -238.2% | — | ||
| Q3 25 | — | -177.4% | ||
| Q2 25 | — | -20.7% | ||
| Q1 25 | — | -32.0% | ||
| Q3 24 | — | -26.8% |
| Q4 25 | $-0.38 | — | ||
| Q3 25 | — | $-0.21 | ||
| Q2 25 | — | $-0.04 | ||
| Q1 25 | — | $-0.07 | ||
| Q3 24 | — | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $9.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $80.0M | $37.4M |
| Total Assets | $140.4M | $42.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | — | ||
| Q3 25 | — | $9.8M | ||
| Q2 25 | — | $4.0M | ||
| Q1 25 | — | $6.8M | ||
| Q3 24 | — | $9.9M |
| Q4 25 | $80.0M | — | ||
| Q3 25 | — | $37.4M | ||
| Q2 25 | — | $10.9M | ||
| Q1 25 | — | $11.9M | ||
| Q3 24 | — | $15.8M |
| Q4 25 | $140.4M | — | ||
| Q3 25 | — | $42.7M | ||
| Q2 25 | — | $16.6M | ||
| Q1 25 | — | $17.3M | ||
| Q3 24 | — | $22.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $-3.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | — | ||
| Q3 25 | — | $-3.5M | ||
| Q2 25 | — | $-1.8M | ||
| Q1 25 | — | $-2.2M | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
